Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor

NeuroImage

Volumn 54, Issue 4, 2011, Pages 2635-2642

  Hostetler, Eric D ^a   Sanabria Bohórquez, Sandra ^a   Fan, Hong ^a   Zeng, Zhizhen ^a   Gantert, Liza ^a   Williams, Mangay ^a   Miller, Patricia ^a   O'Malley, Stacey ^a   Kameda, Minoru ^b   Ando, Makoto ^b   Sato, Nagaaki ^b   Ozaki, Satoshi ^b   Tokita, Shigeru ^b   Ohta, Hisashi ^b   Williams, David ^a   Sur, Cyrille ^a   Cook, Jacquelynn J ^a   Burns, H Donald ^a   Hargreaves, Richard ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Autoradiography; Fluorine 18; Monkey; Neuropeptide Y Y1 receptor; PET

Indexed keywords

CHLORIDE; FLUORINE 18; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; TRACER; UNCLASSIFIED DRUG; Y 1 718; Y 1 973;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN HOMOGENATE; BRAIN STEM; BRAIN TISSUE; CEREBELLUM; CEREBELLUM NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DENTATE GYRUS; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PURITY; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; GLOBUS PALLIDUS; GRAY MATTER; HUMAN; HUMAN TISSUE; HYPOTHALAMUS; ISOTOPE LABELING; NONHUMAN; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN; RADIOCHEMISTRY; RHESUS MONKEY; THALAMUS;

ANIMALS; AUTORADIOGRAPHY; BRAIN; FLUORINE RADIOISOTOPES; HUMANS; MACACA MULATTA; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS; RECEPTORS, NEUROPEPTIDE Y;

EID: 78650927843     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2010.11.014     Document Type: Article

References (26)

1. Adrian T.E., Allen J.M., Bloom S.R., Ghatei M.A., Rossor M.N., Robers G.W., Crow T.J., Tatemoto K., Polak J.M. Neuropeptide Y distribution in human brain. Nature 1983, 306:584-586.
2. Ando, M., Ito, I., Kameda, M., Kawamoto, H., Kobayashi, K., Miyazoe, H., Nakama, C., Sato, N., Tsujino, T., 2009. Alkylaminopyridine Derivative. Patent WO2009110510.
3. Caberlotto L., Fuxe K., Sedval G., Hurd Y. Localization of neuropeptide Y Y1 mRNA in the human brain: abundant expression in cerebral cortex and striatum. Eur. J. Neurosci. 1997, 9:1212-1225.
4. 18F]fluoride ion. Eur. J. Org. Chem. 2008, 2853-2873.
5. Dohta Y., Yamashita T., Horiike S., Nakamura T., Fukami T. A system for LogD screening of 96-well plates using a water-plug aspiration/injection method combined with high-performance liquid chromatography-mass spectrometry. Anal. Chem. 2007, 79:8312-8315.
6. Eckelman W.C., Gibson R.E., Rzeszotarski W.J., Vieras F., Mazaitis J.K., Francis B., Reba W.C. The design of receptor binding radiotracers. Principles of Radiopharmacology 1979, 251-274. CRC Press, New York. L. Colombetti (Ed.).
7. Eckelman W.C., Kilbourn M.R., Mathis C.A. Discussion of targeting proteins in vivo: in vitro guidelines. Nucl. Med. Biol. 2006, 33:449-451.
8. Eva C., Serra M., Mele P., Panzica G.C., Oberto A. Physiology and gene regulation of the brain NPY Y1 receptor. Front. Neuroendocrinol. 2006, 27:308-339.
9. 4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging. Bioorg. Med. Chem. Lett. 2010, 20:950-953.
10. Hamill T.G., Sato N., Jitsuoka M., Tokita S., Sanabria S., Eng W., Ryan C., Krause S., Takenaga N., Patel S., Zeng Z., Williams D., Sur C., Hargreaves R., Burns H.D. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse 2009, 63:1122-1132.
11. Hostetler E.D., Hamill T.G., Francis B.E., Burns H.D. A versatile, commercially available automated synthesizer for the development and production of PET radiotracers. J. Labelled Compd. Radiopharm. 2001, 44:S1042-S1044.
12. Ikoma Y., Watabe H., Shidahara M., Naganawa M., Kimura Y. PET kinetic analysis: error consideration of quantitative analysis in dynamic studies. Ann. Nucl. Med. 2008, 22:1-11.
13. Kameda M., Ando M., Nakama C., Kobayashi K., Kawamoto H., Ito S., Suzuki T., Tani T., Ozaki S., Tokita S., Sato N. Synthesis and evaluation of a series of 2, 4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors. Bioorg. Med. Chem. Lett. 2009, 19:5124-5127.
14. Kanatani A., Hata M., Mashiko S., Ishihara A., Okamoto O., Haga Y., Ohe T., Kanno T., Murai N., Ishii Y., Fukuroda T., Fukami T., Ihara M. A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol. Pharmacol. 2001, 59:501.
15. Keller M., Montgomery S., Ball W., Morrison M., Snavely D., Liu G., Hargreaves R., Hietala J., Lines C., Beebe K., Reines S. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 2006, 59:216-223.
16. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconj. Chem. 2001, 12:1028-1034.
17. Larhammar D., Wraith A., Berglund M.M., Holmberg S.K.S., Lundell I. Origins of the many NPY-family receptors in mammals. Peptides 2001, 22:295-307.
18. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16:834-840.
19. MacNeil D.J. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr. Top. Mec. Chem. 2007, 7:1721-1733.
20. Ohe T., Sato M., Tanaka S., Fujino N., Hata M., Shibata Y., Kanatani A., Fukami T., Yamazaki M., Chiba M., Ishii Y. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab. Dispos. 2003, 31:1251-1254.
21. Reubi J.C., Gugger M., Waser B., Schaer J.C. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res. 2001, 61:4636-4641.
22. Stanley B.G., Magdalin W., Seirafi A., Nguyen M.M., Leibowitz S.F. Evidence for neuropeptide Y mediation of eating produced by food deprivation and for a variant of the Y1 receptor mediating this peptide's effect. Peptides 1992, 13:581-587.
23. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y-a novel brain peptide with strictural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
24. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imag. Biol. 2003, 5:376-389.
25. Yamazaki M., Neway W.E., Ohe T., Chen I.W., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for P-glycoprotein mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 2001, 296:723-735.
26. Zwanziger D., Ullah Khan I., Neundorf I., Sieger S., Lehmann L., Friebe M., Dinkelborg L., Beck-Sickinger A. Novel chemically modified analogues of neuropeptide Y for tumor targeting. Bioconj. Chem. 2008, 19:1420-1438.